Archive | Papers RSS feed for this section

Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects

March 5, 2017

0 Comments

Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK signaling pathways. Here, TRAF6 protein was determined to be overexpressed in bone marrow mononuclear cells (BMMCs) from multiple myeloma (MM) patients. TRAF6 expression in BMMCs from patients with […]

Continue reading...

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

March 5, 2017

0 Comments

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Haematologica December 2016 : haematol.2016.150896; doi:10.3324/haematol.2016.150896 Abstract B-cell maturation antigen is expressed on plasma cells. In this study, we have […]

Continue reading...

Outcomes in Multiple Myeloma Patients Evaluated

March 5, 2017

0 Comments

There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264 individuals. Participants all had multiple myeloma with an initial visit occurring between 2004 and 2014. They had treatment at a clinic that specialized in the disorder. Investigators looked at progression-free, overall, and 5-year overall survival. […]

Continue reading...

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

March 5, 2017

0 Comments

  Ariana Berenson Suzie Vardanyan Michael David James Wang Nika Manik Harutyunyan Jillian Gottlieb Ran Halleluyan Tanya M. Spektor Kyle A. Udd Shahrooz Eshaghian Youram Nassir Benjamin Eades Regina Swift James R. Berenson Abstract New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade. However, most of the studies reporting outcomes […]

Continue reading...

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma

March 5, 2017

0 Comments

Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S. Wang, Haiming Chen and James R. Berenson DOI: 10.1158/1078-0432.CCR-15-2224 Published July 2016 Abstract Purpose: Reduced uninvolved immunoglobulin (Ig) levels are a hallmark of multiple myeloma. We previously showed that B-cell maturation antigen (BCMA) is solubilized and at […]

Continue reading...

Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients

March 5, 2017

0 Comments

Abstract Multiple myeloma (MM) is characterized by the enhanced production of the same monoclonal immunoglobulin (M-Ig or M protein). Techniques such as serum protein electrophoresis and nephelometry are routinely used to quantify levels of this protein in the serum of MM patients. However, these methods are not without their shortcomings and problems accurately quantifying M […]

Continue reading...

A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma

March 5, 2017

0 Comments

Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade […]

Continue reading...

Results of CHAMPION-1: A Phase 1/2 Study of Weekly Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

March 5, 2017

0 Comments

James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal and Jesus G. Berdeja Blood 2016 127:3360-3368; doi: https://doi.org/10.1182/blood-2015-11-683854 Key Points The CHAMPION-1 study is the first clinical trial […]

Continue reading...

Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy

March 5, 2017

0 Comments

J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R A Swift3 and R A Vescio10 1Department of Hematology/Oncology, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA 2Oncotherapeutics, West Hollywood, CA, USA 3James R Berenson, MD, Inc., West Hollywood, CA, USA 4Department of Medical Oncology and Hematology, Central Coast […]

Continue reading...

Advances in the Management of Multiple Myeloma

March 1, 2017

0 Comments

James R Berenson, MD,abc Tanya M Spektor, PhD,c and James Wang, MDab aInstitute for Myeloma and Bone Cancer Research; bJames R Berenson, MD, Inc; and cOncotherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is a consultant for and receives honoraria and research funding from Takeda, Amgen, Jansen, Celgene, and Bristol-Meyers-Squibb. […]

Continue reading...